Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV002468451 | SCV002764297 | uncertain significance | Dilated cardiomyopathy 1W; Hypertrophic cardiomyopathy 15 | 2021-06-11 | criteria provided, single submitter | clinical testing | |
Molecular Genetics, |
RCV003994439 | SCV004812513 | uncertain significance | Primary dilated cardiomyopathy | 2023-08-01 | criteria provided, single submitter | clinical testing | This sequence change in VCL is predicted to replace leucine with proline at codon 448, p.(Leu448Pro). The leucine residue is highly conserved (100 vertebrates, UCSC), and is not located in an annotated domain. There is a moderate physicochemical difference between leucine and proline. This variant is absent from the population database gnomAD v2.1 and v3.1. To our knowledge, this variant has not been previously reported in the relevant scientific literature. The variant has been reported in one individual with atrial fibrillation (ClinVar: SCV002764297.1) Computational evidence predicts a deleterious effect for the missense substitution (REVEL = 0.721). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.6.1, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: PM2_Supporting, PP3 |